8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 22, 2018

 

 

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37702   95-3540776

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Amgen Center Drive

Thousand Oaks, California

  91320-1799
(Address of principal executive offices)   (Zip Code)

805-447-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 22, 2018. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 13 nominees for director were elected to serve a one-year term expiring at the Company’s 2019 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

 

Name

   Votes For      Votes Against      Abstain      Broker Non-
Votes
 

Dr. Wanda M. Austin

     503,998,322        1,532,975        1,723,098        94,370,662  

Mr. Robert A. Bradway

     482,683,636        20,533,009        4,037,750        94,370,662  

Dr. Brian J. Druker

     503,925,059        1,533,025        1,796,311        94,370,662  

Mr. Robert A. Eckert

     501,741,752        3,699,625        1,813,018        94,370,662  

Mr. Greg C. Garland

     476,663,767        28,167,830        2,422,798        94,370,662  

Mr. Fred Hassan

     500,457,465        4,980,779        1,816,151        94,370,662  

Dr. Rebecca M. Henderson

     504,038,046        1,495,588        1,720,761        94,370,662  

Mr. Frank C. Herringer

     495,141,239        10,256,977        1,856,179        94,370,662  

Mr. Charles M. Holley, Jr.

     503,698,630        1,693,900        1,861,865        94,370,662  

Dr. Tyler Jacks

     503,383,287        2,095,894        1,775,214        94,370,662  

Ms. Ellen J. Kullman

     501,410,925        4,122,120        1,721,350        94,370,662  

Dr. Ronald D. Sugar

     500,052,710        5,358,047        1,843,638        94,370,662  

Dr. R. Sanders Williams

     502,911,983        2,505,438        1,836,974        94,370,662  

Item 2 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

 

For:

     479,909,273  

Against:

     24,226,081  

Abstain:

     3,119,041  

Broker Non-Votes:

     94,370,662  

Item 3 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2018. No Broker Non-Votes resulted from the vote on this proposal.

 

For:

     588,359,686  

Against:

     11,221,423  

Abstain:

     2,043,948  


Item 4 - Stockholder Proposal

The stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation was not approved.

 

For:

     129,536,872  

Against:

     371,541,053  

Abstain:

     6,176,470  

Broker Non-Votes:

     94,370,662  

No other matters were submitted for stockholder action.

A copy of the press release announcing the vote results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

99.1 Press Release, dated May 22, 2018


EXHIBIT INDEX

 

Exhibit
No.
  

Document Description

99.1    Press Release, dated May 22, 2018


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AMGEN INC.
Date: May 22, 2018     By:   /s/ Jonathan P. Graham
    Name:   Jonathan P. Graham
    Title:   Senior Vice President, General Counsel and Secretary